Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis

Medicine and Dentistry

• Lung Cancer 100%
• Drug Resistance 100%
• Brain Metastasis 100%
• Cisplatin 20%
• In Vitro 10%
• Cancer Cell 10%
• Patient 10%
• Neoplasm 10%
• Survival 10%
• Pemetrexed 10%
• Etoposide 10%
• Epidermal Growth Factor Receptor 10%
• IC50 10%
• Gefitinib 10%
• Analysis 5%
• Assay 5%
• Combination Therapy 5%
• Quantitative Reverse Transcription Polymerase Chain Reaction 5%
• Drug Therapy 5%
• Metastatic Carcinoma 5%
• Tissue Banking 5%
• Lesion 5%
• Female 5%
• Prognosis 5%
• Paracetamol 5%
• Group Therapy 5%
• Neurologic Disease 5%
• Autoradiograph 5%
• Fluorescence Microscopy 5%
• Carbon 14 5%
• Survival Time 5%
• Uvomorulin 5%
• Radioactive Tracer 5%
• Vimentin 5%
• MTT Assay 5%
• Dying 5%
• Tumor Vascularization 5%
• Indocyanine Green 5%
• Epithelial Mesenchymal Transition 5%
• Ventricle (Heart) 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Resistance 100%
• Lung Cancer 100%
• Brain Metastasis 100%
• Mouse 30%
• Cisplatin 20%
• Survival 10%
• Neoplasm 10%
• Pemetrexed 10%
• Chemotherapy 10%
• Gefitinib 10%
• Etoposide 10%
• IC50 10%
• Animal 5%
• Microscopy 5%
• Metastasis 5%
• Pharmaceutical Therapy 5%
• Paracetamol 5%
• Prognosis 5%
• Brain Injury 5%
• Indocyanine Green 5%
• Neurologic Disease 5%
• Tracer 5%
• Survival Time 5%
• Carbon 14 5%
• Nude Mouse 5%
• Uvomorulin 5%
• Autoradiography 5%
• Vimentin 5%
• Tumor Vascularization 5%
• 2 Amino 2 Methylpropionic Acid 5%
• Dying 5%

Neuroscience

• Brain 100%
• Brain Cancer 100%
• Drug Resistance 100%
• Metastasis 100%
• Cisplatin 20%
• In Vitro 10%
• Etoposide 10%
• Gefitinib 10%
• Pemetrexed 10%
• In Vivo 5%
• Chemotherapy 5%
• Brain Lesion 5%
• Uvomorulin 5%
• Vimentin 5%
• MTT Assay 5%